Search

Objectives: Rhus coriaria L. (RC) is a deciduous shrub with several pharmacological activities. Evidence of the effects of RC on weight, hyperlipidaemia, hypertension and diabetes mellitus have been presented in this study. Books, thesis and internet-based resources such as PubMed, Web of Science, Scopus, EMBASE, Cochrane, Ovid and Google Scholar were searched for the English, Arabic and Persian literature from 1966 to 2020 (December). The keywords were Rhus coriaria L., Sumac, metabolic syndrome and all its medical conditions (hyperlipidaemia, hypertension, obesity and diabetes mellitus). The inclusion criteria were full-text animal and human studies conducted on RC to evaluate its efficacy on any components of metabolic syndrome (MetS). Jadad scale was used to assess the quality of evidence. Key findings: Reviewing 23 relevant studies demonstrated that RC is able to decrease the level of blood glucose, glycated haemoglobin, serum insulin and insulin resistance. Studies on hyperlipidaemia and obesity have very contradicting results, and there is no definite conclusion on the effect of RC on lipid profile. However, the hypotensive and effect of RC was confirmed in the existing studies. Summary: According to the literature, RC can be considered as a promising curative candidate for MetS. However, further studies with larger sample size and higher methodological quality are needed. [ABSTRACT FROM AUTHOR]

Aim of the study: The suicide risk in patients with eating disorders is 5-6 times higher than that of the general population. Due to the high likelihood of re-suicide in suicide survivors, in this study, we investigated the prevalence of the anorexia nervosa and bulimia nervosa among women who recently attempted suicide compared with suicide non-attempting women. Materials and Methods: In this case-control study, two groups of 30 women aged 15-45-year-old were investigated after a suicide attempt. Case group was admitted to the Razi Hospital poisoning ward and the control group was admitted to other wards of the hospital. Data were collected using the EAT-26 questionnaire and a clinical interview based on the SCID-V. Finally, the results were analyzed using the SPSS version 21. Results: The both groups' mean age was 26.96± 6.3 and 27.2±7.16 years, respectively. There was no significant difference in age, employment status, marital status, and education level between the two groups (P>0.05). The prevalence of both disorders did not show a significant interaction with demographic characteristics. The average prevalence of both disorders among the case group was 32.78±8.1 and 37.42±7.21, respectively, and was significantly different in women who had recently attempted suicide compared to their counterparts (p <0.05). Discussion: Our findings are consistent with all previously conducted studies. Conclusion: The prevalence of these disorders was significantly higher in women who had recently committed suicide compared to the control group (p <0.05), although there was no significant difference in the prevalence of both disorders with other sociodemographic factors. [ABSTRACT FROM AUTHOR]

Introduction: Antidepressants are the most common treatment for major depression. Also, psychotherapy is used for the treatment of depression. Tricyclic antidepressants are among the most frequently used medications to treat depression, with many known side effects. Therefore, checking and replacing other suitable drugs is essential in order to reduce side effects. Thus, the present study aimed to compare the efficacy of Modafinil and Citalopram in the treatment of patients with major depressive disorder. Method: This interventional study was performed in 2019 on 30 people aged 18 to 65 years who had been diagnosed with a major depressive disorder based on DSM-5 criteria as well as the Hamilton Depression Rating Scale (HDRS), on which they got a score above 25. Subjects were randomly divided into two groups: the first group received Modafinil tablets (200 mg once daily, in the morning) and the second group Citalopram (20-40 mg/day). A Chi-square test was used to analyze the qualitative findings, and an independent t-test was used to compare quantitative data. Results: The results showed that changes in HDRS score were significant over time (P <0.05). The mean difference in HDRS scores was significant in all stages among the study subjects (P <0.05). However, there were no significant differences in HDRS scores between groups in terms of gender, age, marital status, education, occupation, and economic status, either before treatment or three and six weeks after treatment. Conclusion: This was the first comparative study of Modafinil and Citalopram efficacy in treating patients with major depressive disorder. Larger-scale, longer-term clinical trials, including long-term discontinuation trials and placebo-controlled parallel treatment studies, are further necessary. Also, a larger sample size with a placebo comparison is recommended. [ABSTRACT FROM AUTHOR]